SCYX SCYNEXIS, Inc.
$4.84▲ +2.98%
Healthcare
Other
After hours
$4.84▲ +0.00%
Sep 11, 7:30 PM ET
Volume 30.4K
Avg Volume (10D) 52.9K
Key Metrics & Fundamentals
Market Cap
$48.16M
P/E Ratio
–
Div Yield
–%
52W Range
3.53 - 10.48
% vs 50 MA
1.14%
% vs 200 MA
-15.01%
RSI-14
45.1
MACD Histogram
-0.0900
Beta (1Y vs SPY)
1.32
Free Cash Flow
-$14.89M
Gross Rev
$235,000
Gross Profit
$235,000
EBITDA
-$6.76M
COGS
–
Operating Exp
$8.01M
Operating Income
-$7.78M
EBIT
-$7.78M
Pretax Income
$7.40M
Net Income
$7.40M
EPS (Diluted)
0.63
Price & Volume History
Loading chart…
Recent News
SCYNEXIS Names Sanjay Subramanian as CFO
MT Newswires · Sep 10, 2026 12:57 PM
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
GlobeNewswire · Sep 10, 2026 12:00 PM
SCYNEXIS to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 12:30 PM
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 25, 2026 11:06 PM
Scynexis: Q2 Earnings Snapshot
Associated Press · Aug 10, 2026 8:56 PM
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 10, 2026 8:30 PM
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
GlobeNewswire · Jun 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See SCYX's money flow as a full page
Social Sentiment
No Reddit posts found for SCYX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.